Sammanfattning
Norway is no longer self-sufficient in plasma products. The shortfall is covered from the commercial plasma market, in which plasma from paid blood donors is included as a source. This conflicts with the altruistic foundation of the transfusion services. There is also a risk of a supply crisis with regard to cellular blood components. A long-term effort is required to redress the balance between production and consumption in the transfusion services.